Generation Bio (NASDAQ:GBIO) Posts Earnings Results, Misses Estimates By $0.01 EPS

Generation Bio (NASDAQ:GBIO) released its quarterly earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01), Zacks reports. Generation Bio had a negative return on equity of 104.85% and a negative net margin of 782.86%. The company had revenue of $4.19 million for the quarter, compared to analysts’ expectations of $2.92 million.

Generation Bio Trading Down 6.3 %

GBIO stock opened at $0.48 on Friday. The firm has a 50 day moving average of $0.74 and a 200-day moving average of $1.53. Generation Bio has a 12-month low of $0.47 and a 12-month high of $4.65. The company has a market cap of $32.06 million, a price-to-earnings ratio of -0.22 and a beta of 2.72.

Insider Activity

In related news, Director Anthony G. Quinn acquired 85,000 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was purchased at an average cost of $0.97 per share, for a total transaction of $82,450.00. Following the transaction, the director now directly owns 299,286 shares of the company’s stock, valued at approximately $290,307.42. This trade represents a 39.67 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 21.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Generation Bio in a report on Friday. Wedbush reaffirmed an “outperform” rating and issued a $5.00 price objective on shares of Generation Bio in a report on Friday.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.